Bioxytran (BIXT) News Today → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free BIXT Stock Alerts $0.13 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | americanbankingnews.comShort Interest in Bioxytran, Inc. (OTCMKTS:BIXT) Grows By 192.4%March 20, 2024 | msn.comBIXT: Carbohydrate Drug Design in the Fight Against VirusesMarch 6, 2024 | globenewswire.comBioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 AntagonistFebruary 21, 2024 | finance.yahoo.comBioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19February 21, 2024 | globenewswire.comBioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19October 24, 2023 | finance.yahoo.comBioxytran Gets Broad Patent Coverage on 60+ VirusesSeptember 14, 2023 | finance.yahoo.comBioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-MSeptember 6, 2023 | benzinga.comBioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patientsAugust 25, 2023 | msn.comFDA grants clearance to Bioxytran’s IND for Covid-19 trial initiationAugust 24, 2023 | finance.yahoo.comBioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical TrialsAugust 8, 2023 | finance.yahoo.comBioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 PatientsJuly 31, 2023 | finance.yahoo.comBioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory BoardJune 27, 2023 | it.tmcnet.comBioxytran Peer-Reviewed Journal in "Vaccines" Contains Mechanism Capable of Targeting Future COVID-19 MutationsJune 27, 2023 | finance.yahoo.comBioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 MutationsJune 12, 2023 | msn.comBioxytran expands institutional investor base with $0.5M equity investmentJune 12, 2023 | finance.yahoo.comBioxytran Expands Institutional Investor Base with an additional $500,000 Equity InvestmentApril 19, 2023 | finance.yahoo.comBioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical TrialsMarch 29, 2023 | tmcnet.comBioxytran Announces Positive Phase 2 Trial Results were Featured in "Vaccines" a Peer-Reviewed JournalMarch 29, 2023 | finance.yahoo.comBioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed JournalMarch 6, 2023 | finance.yahoo.comBioxytran, Inc. (BIXT) Stock Historical Prices & Data - Yahoo FinanceFebruary 28, 2023 | finance.yahoo.comProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial VirusFebruary 22, 2023 | finance.yahoo.comNature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral DrugFebruary 14, 2023 | finance.yahoo.comBioxytran to Appear on ClearThink IR’s Virtual Live EventFebruary 8, 2023 | proactiveinvestors.comBioxytran drug candidates ProLectin-M and ProLectin-I progressing as COVID-19 treatmentsFebruary 6, 2023 | finance.yahoo.comBioxytran Receives Approval to Initiate Trials with ProLectin-IDecember 28, 2022 | marketwatch.comBioxytran Shares Rise 20% on Trial Results for Covid-19 DrugDecember 28, 2022 | msn.comBioxytran chewable drug for COVID-19 meets phase 2 trial's goalsDecember 28, 2022 | finance.yahoo.comCrystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 TrialDecember 14, 2022 | finance.yahoo.comBioxytran Establishes Indian Subsidiary in Preparation of CommercializationDecember 12, 2022 | finance.yahoo.comBioxytran Interview at the Emerging Growth ConferenceDecember 8, 2022 | markets.businessinsider.comBioxytran Gets Approval In India To Optimize Dosage In COVID-19 PatientsDecember 8, 2022 | finance.yahoo.comBioxytran Receives Approval to Optimize Dosage in COVID-19 PatientsNovember 22, 2022 | finance.yahoo.comBioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise AnalyticsNovember 16, 2022 | finanznachrichten.deFinancialnewsmedia.com: While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat SubvariantsNovember 16, 2022 | markets.businessinsider.comBIOXYTRAN Announces Positive Mid-stage Study Results Of Galectin Antagonist In Covid PatientsNovember 16, 2022 | finance.yahoo.comBioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-printOctober 25, 2022 | finance.yahoo.comBioxytran Scientific Advisor Releases New Book on Brain MetabolismSeptember 16, 2022 | seekingalpha.comEnding The Pandemic Cycle - Bioxytran’s (BIXT) Galectin ApproachAugust 17, 2022 | reuters.comBIXT.PK - Bioxytran Inc | Stock Price & Latest News | ReutersAugust 1, 2022 | finance.yahoo.comNovel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 CoronavirusJanuary 24, 2022 | nasdaq.comBIXT Real-Time Quotes Get Bioxytran News Delivered to You Automatically Sign up to receive the latest news and ratings for BIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words? I believe I have the terrifying answer right here. BIXT Media Mentions By Week BIXT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIXT News Sentiment▼0.980.42▲Average Medical News Sentiment BIXT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIXT Articles This Week▼10▲BIXT Articles Average Week Get Bioxytran News Delivered to You Automatically Sign up to receive the latest news and ratings for BIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Benitec Biopharma News Today Cumberland Pharmaceuticals News Today CytoMed Therapeutics News Today MEI Pharma News Today Bullfrog AI News Today Orgenesis News Today Lumos Pharma News Today Alaunos Therapeutics News Today TherapeuticsMD News Today Synlogic News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BIXT) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryMissed NVDA? Buy this AI stock NOWChaikin AnalyticsMost important medical advance in 100 yearsThe Oxford Club41 banks launch ‘crypto dollar’Stansberry ResearchDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
